Cormorant Asset Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Cormorant Asset Management’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,040,021	Closed	-$64.1M	–	86
2020 Q1	$64.1M	Sell	2,040,021 -259,979	-11%	-$9.04M	2.98%	10
2019 Q4	$108M	Buy	2,300,000 +1,086,726	+90%	+$31.4M	4.32%	6
2019 Q3	$7.84M	Sell	1,213,274 -58,411	-5%	-$488K	0.48%	51
2019 Q2	$15.6M	Sell	1,271,685 -2	-0%	-$22	0.9%	34
2019 Q1	$17.2M	Hold	1,271,687	–	–	1.16%	29
2018 Q4	$5.1M	Hold	1,271,687	–	–	0.41%	46
2018 Q3	$8.56M	Buy	+1,271,687	New	+$12.1M	0.56%	39

Other funds holding CNST

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMV

Venrock Management V Palo Alto, California $719M AUM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Cormorant Asset Management's CNST Position: Q2 2020 in Review

Cormorant Asset Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2020, closing a stake of 2,040,021 shares — an estimated $64.1M sold.

Cormorant Asset Management first reported a position in CNST in Q3 2018 and held it in 7 quarters. The position peaked at $108M in Q4 2019. 132 funds tracked by Wall St. Rank hold CNST as of Q2 2020.

Cormorant Asset Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Cormorant Asset Management sold 2,040,021 Constellation Pharmaceuticals, Inc. shares in Q2 2020, an estimated $64.1M.
Cormorant Asset Management first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 7 quarters.
Cormorant Asset Management's Constellation Pharmaceuticals, Inc. position peaked at $108M in Q4 2019.
132 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2020.

Based on Cormorant Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.